Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Fig. 3

LTX-315 in combination with single-dose CAELYX® induced complete regression of tumors in the majority of animals. Representative bioluminescent (a) and magnetic resonance (b) images from animals treated with vehicle, CAELYX® alone, LTX-315 alone, or LTX-315 in combination with CAELYX®. Baseline was defined as day 7, and the study was performed as illustrated in experiment 1 in Fig. 1. Animals were scanned at the regular interval of once per week

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us